Literature DB >> 8846199

Cytokine production by phytohemagglutinin-stimulated human blood cells: effects of corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors.

J Van Wauwe1, F Aerts, H Walter, M de Boer.   

Abstract

The ability of dexamethasone and prednisolone (corticosteroids), FK506 and cyclosporin A (T cell immunosuppressants), and of nitraquazone and rolipram (phosphodiesterase IV inhibitors) to inhibit cytokine production by stimulated human blood was investigated. Heparinized human blood obtained from normal healthy volunteers was stimulated with phytohemagglutinin (PHA) in the presence or absence of drug. After different incubation times, supernatant levels of interleukin (IL)-2, IL-5, granulocyte-macrophage colony stimulating factor (GM-CSF) and interferon gamma (IFN-gamma) were quantified by ELISA. Dexamethasone strongly inhibited the production of IL-5 (IC50 = 0.004 microM), was less potent against IL-2 and IFN-gamma (IC50 = 0.02-0.05 microM) and showed a relatively weak effect against GM-CSF (IC50 = 0.6 microM). Similarly prednisolone potently suppressed IL-5 generation (IC50 = 0.05 microM), displayed a more modest activity on IL-2 and IFn-gamma (IC50 = 0.2-0.3 microM) and exerted only partial effects (43% inhibition at 1 microM) on GM-CSF). FK506 strongly suppressed the production of IL-2 (IC50 = 0.01 microM) and GM-CSF (IC50 = 0.03 microM), but was inactive (< 30% inhibition at 1 microM) against IL-5 and IFN-gamma. Similarly, cyclosporin A reduced the generation of IL-2 (IC50 = 0.4 microM) and GM-CSF (IC50 = 0.6 microM) while barely affecting the other two cytokines. Nitraquazone and rolipram were most active in reducing the production of IL-5 (IC50 = 0.8 and 1.3 microM, respectively), while their potency against IL-2, GM-CSF and IFN-gamma was 3-6 times lower, with IC50's between 2.4 and 8.0 microM. These data indicate that corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors affect cytokine production by PHA-stimulated human blood cells in a differential and "pharmacotypical'' manner.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8846199     DOI: 10.1007/bf01797868

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  35 in total

Review 1.  Interleukin-5, eosinophils, and disease.

Authors:  C J Sanderson
Journal:  Blood       Date:  1992-06-15       Impact factor: 22.113

Review 2.  FK506 and cyclosporin, molecular probes for studying intracellular signal transduction.

Authors:  J Liu
Journal:  Immunol Today       Date:  1993-06

Review 3.  Isozyme-selective cyclic nucleotide phosphodiesterase inhibitors: biochemistry, pharmacology and therapeutic potential in asthma.

Authors:  D Raeburn; J E Souness; A Tomkinson; J A Karlsson
Journal:  Prog Drug Res       Date:  1993

Review 4.  Interleukin-5 and its receptor system: implications in the immune system and inflammation.

Authors:  K Takatsu; S Takaki; Y Hitoshi
Journal:  Adv Immunol       Date:  1994       Impact factor: 3.543

Review 5.  The molecular cell biology of interferon-gamma and its receptor.

Authors:  M A Farrar; R D Schreiber
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

6.  Mechanism of inhibition of Raf-1 by protein kinase A.

Authors:  S Häfner; H S Adler; H Mischak; P Janosch; G Heidecker; A Wolfman; S Pippig; M Lohse; M Ueffing; W Kolch
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

7.  The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells.

Authors:  J Semmler; H Wachtel; S Endres
Journal:  Int J Immunopharmacol       Date:  1993-04

8.  Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements.

Authors:  A Vacca; M P Felli; A R Farina; S Martinotti; M Maroder; I Screpanti; D Meco; E Petrangeli; L Frati; A Gulino
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

9.  Prostaglandin E2 and other cyclic AMP elevating agents inhibit interleukin 2 gene transcription by counteracting calcineurin-dependent pathways.

Authors:  F Paliogianni; R L Kincaid; D T Boumpas
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

10.  Differential regulation of TNF-alpha and IL-1beta production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors.

Authors:  K L Molnar-Kimber; L Yonno; R J Heaslip; B M Weichman
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

View more
  8 in total

1.  PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis.

Authors:  L Mestre; M Redondo; F J Carrillo-Salinas; J A Morales-García; S Alonso-Gil; A Pérez-Castillo; C Gil; A Martínez; C Guaza
Journal:  Br J Pharmacol       Date:  2015-07-14       Impact factor: 8.739

Review 2.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

3.  Differential effect of phosphodiesterase inhibitors on IL-13 release from peripheral blood mononuclear cells.

Authors:  N Yoshida; Y Shimizu; K Kitaichi; K Hiramatsu; M Takeuchi; Y Ito; H Kume; K Yamaki; R Suzuki; E Shibata; T Hasegawa; K Takagi
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

4.  FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells.

Authors:  S Sakuma; Y Kato; F Nishigaki; T Sasakawa; K Magari; S Miyata; Y Ohkubo; T Goto
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

5.  Intracellular T lymphocyte cytokine profiles in the aqueous humour of patients with uveitis and correlation with clinical phenotype.

Authors:  T Hill; G Galatowicz; T Akerele; C H Lau; V Calder; S Lightman
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

6.  Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE).

Authors:  A Csiszár; G Nagy; P Gergely; T Pozsonyi; E Pócsik
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

7.  The inhibitory effect of pentamidine on the production of chemotactic cytokines by in vitro stimulated human blood cells.

Authors:  J Van Wauwe; F Aerts; H Van Genechten; H Blockx; W Deleersnijder; H Walter
Journal:  Inflamm Res       Date:  1996-07       Impact factor: 4.575

8.  Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors.

Authors:  A Nakata; K Ogawa; T Sasaki; N Koyama; K Wada; J Kotera; H Kikkawa; K Omori; O Kaminuma
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.